A Randomized, Double-blinded, Multi-center, Phase III Study to Compare The Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia
A Randomized, Double-blinded, Multi-center, Phase III Study to Compare The Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia
A Randomized, Double-blinded, Multi-center, Phase III Study to Compare The Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 versus HCP1701 in Patients with Hypertension and Dyslipidemia
Inclusion Criteria:
Exclusion Criteria:
Patients with differences between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP
Patients with mean sitSBP ≥ 180 mmHg or mean sitDBP ≥ 110 mmHg
Concomitant administration of cyclosporine
Tolerance or Hypersensitivity Angiotensin II receptor blocker or HMG-CoA reductase inhibitor, Calcium channel blocker(dihydropyridine) or Multi-drug allergy
Hereditary angioedema or medical history of angioedema in the treatment of ACE inhibitors or angiotensin II receptor blockers
Fibromyalgia, myopathy, rhabdomyolysis or acute myopathy or medical history of adverse effect to statin
CPK normal range > 2 times
Secondary hypertension and suspected secondary hypertension
Orthostatic hypotension with symptoms
Uncontrolled primary hypothyroidism(TSH normal range ≥ 1.5 times)
Severe hepatopathy or active hepatopathy (AST or ALT normal range ≥ 3 times)
Active gout or hyperuricemia(uric acid ≥ 9mg/dL)
IDDM or uncontrolled type 2 diabetes mellitus (HbA1c > 9%)
Ventricular arrhythmia
Medical history